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ORIGINAL RESEARCH ARTICLE
Gender differences in clinical presentation and 1-year 
outcomes in atrial fibrillation
Renate B Schnabel,1 Ladislav Pecen,2 Francisco M Ojeda,1 Markus Lucerna,3 
Nargiz Rzayeva,1 Stefan Blankenberg,1 Harald Darius,4 Dipak Kotecha,5 
Raffaele De Caterina,6,7 Paulus Kirchhof8,9
ABSTRACT
Objectives Our objective was to examine gender differ-
ences in clinical presentation, management and progno-
sis of atrial fibrillation (AF) in a contemporary cohort.
Methods In 6412 patients, 39.7% women, of the 
PREvention oF thromboembolic events – European 
Registry in Atrial Fibrillation, we examined gender 
differences in symptoms, risk factors, therapies and 
1-year incidence of adverse outcomes.
Results Men with AF were on average younger than 
women (mean±SD: 70.1±10.7 vs 74.1±9.7 years, 
p<0.0001). Women more frequently had at least one 
AF-related symptom at least occasionally compared with 
men (95.4% in women, 89.8% in men, p<0.0001). 
Prescription of oral anticoagulation was similar, with an 
increase of non-vitamin K antagonist oral anticoagulants 
from 5.9% to 12.6% in women and from 6.2% to 
12.6% in men, p<0.0001 for both. Men were more 
frequently treated with electrical cardioversion and 
ablation (20.6% and 6.3%, respectively) than women 
(14.9% and 3.3%, respectively), p<0.0001. Women 
had 65% (OR: 0.35; 95% CI (0.22 to 0.56)) lower 
age-adjusted and country-adjusted odds of coronary 
revascularisation, 40% (OR: 0.60; (0.38 to 0.93)) lower 
odds of acute coronary syndrome and 20% (OR: 0.80; 
(0.68 to 0.96)) lower odds of heart failure at 1 year. 
There were no statistically significant gender differences 
in 1-year stroke/transient ischaemic attack/arterial 
thromboembolism and major bleeding events.
Conclusion In a 'real-world' European AF registry, women 
were more symptomatic but less likely to receive invasive 
rhythm control therapy such as electrical cardioversion or 
ablation. Further study is needed to confirm that these 
differences do not disadvantage women with AF.
INTRODUCTION
Atrial fibrillation (AF) is one of the most frequent 
cardiovascular diseases and a common comorbidity in 
older adults in both men and women.1 Gender differ-
ences in AF risk factor distribution, comorbidities, 
clinical presentation and cardiovascular outcomes in 
individuals with AF have been discussed in the litera-
ture in different settings and with conflicting results.2 
3 In prior studies, women with AF carried a higher 
risk of adverse events such as stroke.2 The higher risk 
in women is taken into account in current clinical risk 
algorithms such as the CHA2DS2–VASc (congestive 
heart failure, hypertension, age ≥75 years, diabetes 
mellitus, stroke, vascular disease, age 65–74 years, 
sex category) score.3 Additionally, women appear to 
have a lower bleeding risk than men.4 Less evidence 
is available on the impact of gender on the complex 
interaction between AF and heart failure5 and acute 
coronary syndromes,6 which have been increasingly 
recognised as serious sequelae of AF. In addition, 
gender-specific clinical predictors of maintenance of 
sinus rhythm or adequate rate control are sparsely 
investigated.
Some data suggest gender differences in treat-
ment and response to interventions.4 5 Over the last 
years, many changes have been witnessed, including 
an increased prevalence of AF, the introduction of 
novel therapies and the release of new guidelines.7 
In particular, non-vitamin K antagonist oral antico-
agulants (NOACs) are increasingly used for stroke 
prevention in AF.6 Limited data exist on the impact 
of gender on prescription and continuation of 
NOACs since the implementation of new AF guide-
lines. Guidelines recommend that physicians should 
offer effective diagnostic tools and therapeutic 
management to women and men equally.7
The PREvention oF thromboembolic events – 
European Registry (PREFER) in AF is a prospec-
tive, observational cohort8 implemented to describe 
the management of patients with AF in Europe after 
the release of the 2010 European Society of Cardi-
ology Guidelines for the Management of Atrial 
Fibrillation.9 In this study, we focus on gender differ-
ences in baseline risk factors, disease history and AF 
symptoms, together with therapeutic approaches 
and 1-year incidence of major outcomes. Our aim 
is to highlight potential treatment discrepancies in 
women and men that could impact the prognosis of 
patients with AF.
METHODS
Study sample
Between January 2012 and 2013, the PREFER in 
AF registry enrolled 7243 patients aged 18 years 
and older with physician-verified AF across seven 
Western European countries (France, Germany, 
Austria, Switzerland, Italy, Spain and the UK).8 
Eighty-nine per cent of the study participants were 
treated by cardiologists and recruited from both 
physician offices and hospitals. One-year follow-up 
data were obtained from 6412 patients by physi-
cian-administered questionnaire and medical chart 
information. The last follow-up was performed 
in January 2014. Information on individuals 
without valid follow-up information is provided in 
 Supplementary table 1.
Cardiac risk factors and prevention
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Clinical evaluations
AF had to be present on an ECG or in the readout of an 
implanted device (pacemaker/defibrillator) within the preceding 
12 months. Demographic data, clinical variables, disease history 
and treatment were ascertained by the treating physician. Symp-
toms related to AF were assessed using the European Heart 
Rhythm Association (EHRA) score10 and included symptoms 
such as palpitations, fatigue, dizziness, dyspnoea, chest pain and 
anxiety. The scoring ranged from never, occasional (less than 
once per month), intermediate (once per month to almost daily) 
to frequent (at least daily). An individual’s EHRA score was 
assessed by the treating physician as the maximum score of any 
of the six individual symptom categories. We also assessed the 
EHRA score in individuals with new-onset AF, which was defined 
as AF diagnosed fewer than 90 days prior to enrolment. Lack of 
guideline compliance indicates lack of treatment with oral anti-
coagulant in the previous 12 months despite guideline indica-
tion without contraindication. Adequate heart rate control was 
defined as a heart rate between 60 and 100 bpm during the clinic 
visit. The risk of thromboembolic and bleeding events in patients 
with AF was assessed by calculating the CHA2DS2VASc score 
and HAS-BLED (hypertension, abnormal renal/liver function, 
stroke, bleeding history or predisposition, labile international 
normalised ratio, elderly, drugs/alcohol concomitantly) score.11
Statistical analyses
Data analysis was performed as a substudy of the PREFER in 
AF registry on the 6412 patients with follow-up information. 
Complete case analysis was performed, and missing data were 
assumed to be missing at random. The proportion of women 
and men lost to follow-up was compared by Fisher’s exact test. 
Variables are presented as number (percentage) or mean (±SD), 
as appropriate. Differences by gender across EHRA score cate-
gories for each EHRA symptom and across type of anticoagu-
lation therapy were calculated using Freeman-Halton’s exten-
sion of Fisher’s exact test. Gender differences in dichotomous 
baseline characteristics and the 1-year incidence of four major 
medical sequelae of AF (ischaemic stroke/transient ischaemic 
attack (TIA)/arterial thromboembolic events, acute coronary 
syndrome (myocardial infarction and unstable angina pectoris), 
coronary revascularisation, heart failure and major bleeding 
events) were examined by multiple logistic regression adjusted 
for age and country.
One-year predictive models
An initial round of variable selection was performed, where highly 
collinear variables and variables with a high number of missing 
values and/or few events were removed. Subsequently, predictor 
variables for each logistic regression model were selected by 
stepwise regression (p=0.20 for selection and p<0.05 to remain 
in the model). The list of included predictor variables can be 
found in Suplementary table 2. Age, gender and country were 
forced into the regression models. For the outcome heart failure 
(chronic heart insufficiency and reduced left ventricular ejection 
fraction), patients with the condition at baseline were excluded 
from the analysis. Effect estimates for each model are presented 
separately for women and men. The predictive ability of the 
derived regressions models compared with the CHA2DS2–VASc 
and HAS-BLED scores for each outcome was assessed by calcu-
lating the area under the receiver operating characteristic curve 
(AUC), with overoptimism corrected by repeated  split-sample 
validation (logistic regression and then AUC computation in 
randomly split halves of the sample, repeated 100 times).
Analyses were conducted using SAS software V.9.4 (Cary, 
North Carolina, USA), with a two-tailed significance value of 
0.05. Graphics were produced with R V.3.3.0 using the ggplot2 
package.12 13
RESULTS
Baseline patient characteristics
Forty per cent of study participants were women, who 
were on average 4 years older than men (74.1±9.7 years vs 
70.1±10.7 years, respectively). The body mass index was 
comparable in both genders (28.2±4.7 SD in men vs 27.6±5.4 
SD in women), and the systolic blood pressure was lower in 
men than in women (130.5±16.1 SD in men vs 132.7±17.4 
SD in women). There were numerous differences in the burden 
of cardiovascular risk factors and comorbidities according to 
gender (table 1). Hyperthyroidism, valvular heart disease and 
antiarrhythmic drug intake were more prevalent in women 
than in men. Most other cardiovascular risk factors and preva-
lent disease were more often observed in men. Adequate heart 
control was comparable in women and men. There was no statis-
tically significant gender difference in the proportion of individ-
uals lost to follow-up, p=0.27.
Atrial fibrillation symptoms
In men, 90% experienced symptoms, compared with 95% in 
women. Male study participants reported less severe symptoms 
and showed a lower frequency of symptoms compared with 
women (figure 1). In both genders, the most common symptoms 
were fatigue, dyspnoea and palpitations. At least occasional 
fatigue was reported by 70% of men and 80% of women. The 
least common symptom was chest pain (28% in men and 32% 
in women). The proportions of symptom distribution did not 
change markedly over the follow-up period (data not shown). 
In patients with new-onset AF, symptoms were also distributed 
similarly with women having consistently more frequent symp-
toms (see Suplementary table 3).
Anticoagulation therapies
Anticoagulation therapy was prescribed in 94% of both women 
and men. The majority of patients (>60%) were prescribed 
vitamin K antagonists at both baseline and 1-year follow-up 
(figure 2). At both timepoints, more women than men were 
prescribed vitamin K antagonists only (baseline: 70% vs 65%; 
follow-up: 63% vs 61%), and conversely, more men than women 
were on a combined vitamin K antagonist and antiplatelet 
therapy regimen (baseline: 12% vs 7.0%; follow-up: 7% vs 4%). 
A twofold increase in the use of NOACs was demonstrated in 
both women and men, from about 6% at baseline to 13% at the 
1-year follow-up.
Therapies to restore sinus rhythm
Pharmacological and electrical cardioversion attempts were the 
most common interventions to restore sinus rhythm (table 2). 
At baseline, women were more likely to have undergone a phar-
macological cardioversion attempt compared with men (OR 
1.24; 95% CI 1.08 to 1.41). Men had more frequently received 
electrical cardioversion, catheter ablation (pulmonary vein isola-
tion) or surgical ablation therapy compared with women. The 
point estimates for these ORs were similar at 1-year follow-up, 
although CIs were wider due to the smaller number of proce-
dures. Treatment varied by country, but the proportion of 
women and men receiving a specific therapy was comparable 
across European countries (data not shown).
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Incidence of major outcomes
There was no evidence that men and women differed in the 
two outcomes: stroke/TIA/arterial thromboembolic events and 
major bleeding events (OR 1.08,  95% CI (0.76 to 1.53) and OR 
0.91, (0.67 to 1.24), respectively) (figure 3). Women had lower 
age-adjusted and country-adjusted odds of coronary revascular-
isation (OR 0.35, 95% CI (0.22 to 0.56)), lower odds of acute 
coronary syndrome (OR 0.60, (0.38 to 0.93)), and lower odds 
of heart failure (OR 0.80, (0.68 to 0.96)).
One-year predictive models of major outcomes
The stepwise regression results for each outcome are presented 
in Suplementary table 4-8t. Overall, there was no evidence that 
the strength of association between selected predictors and 
outcomes differed markedly between genders.
The predictive ability (AUC index) of our models performed 
similar to the established CHA2DS2–VASc and HAS-BLED scores 
for stroke/TIA/arterial thromboembolic events and major bleeding 
( Suplementary table 9) in both genders. Overall, the predictive 
abilities of all models were moderate (AUC range: 0.58–0.69).
DISCUSSION
Main findings
In a prospective European registry of patients with AF, women 
presented with different clinical baseline characteristics 
including disease history, AF symptoms, therapies to restore 
sinus rhythm and 1-year incidence of major cardiovascular 
outcomes. Women were older on average and showed a lower 
risk of acute coronary syndrome, coronary revascularisation 
events and development of heart failure compared with men 
over the 1-year follow-up. There was no evidence of gender 
differences for arterial thromboembolic events or bleeding. We 
report possible differences between gender in the strength of 
association of clinical predictors and outcomes, suggesting that a 
gender-specific risk assessment and intervention strategies could 
be of advantage.
Table 1 Baseline characteristics of the PREFER in AF study participants by gender
Variables Women (n=2546) Men (n=3866) Women-to-men OR* 95% CI
Risk factors
Age, years (SD) 74.1 (9.7) 70.1 (10.7)
Body mass index, kg/m² (SD) 27.6 (5.4) 28.2 (4.7)
Systolic blood pressure, mm Hg (SD) 132.7 (17.4) 130.5 (16.1)
Ever smoking, n (%) 452 (18.2) 1958 (51.9) 0.21 (0.19 to 0.24)
Alcohol excess (≥8 units/week), n (%) 14 (0.6) 149 (3.9) 0.16 (0.09 to 0.27)
Lack of guideline compliance in anticoagulant therapy, n (%) 79 (3.1) 83 (2.2) 1.17 (0.85 to 1.62)
EHRA score>2, n (%) 1564 (62.1) 1899 (49.6) 1.68 (1.51 to 1.87)
CHA2DS2–VASc ≥2
†, n (%) 2235 (95.2) 2823 (78.9) 5.55 (4.26 to 7.22)
HAS-BLED≥2, n (%) 1483 (70.8) 2072 (65.4) 0.85 (0.74 to 0.97)
Disease history
Diabetes mellitus, n (%) 529 (21.0) 893 (23.3) 0.82 (0.73 to 0.93)
Dyslipidaemia, n (%) 1035 (41.6) 1745 (46.2) 0.80 (0.72 to 0.88)
Chronic renal insufficiency, n (%) 321 (12.9) 521 (13.8) 0.73 (0.63 to 0.85)
Chronic hepatic disease, n (%) 53 (2.1) 72 (1.9) 1.00 (0.70 to 1.45)
Hyperthyroidism, n (%) 130 (5.2) 137 (3.6) 1.50 (1.17 to 1.93)
Chronic obstructive pulmonary disease, n (%) 252 (10.0) 475 (12.4) 0.68 (0.57 to 0.80)
Major gastrointestinal/cerebrovascular/ other bleeding events, n (%) 98 (3.9) 168 (4.4) 0.80 (0.62 to 1.04)
Prevalent cardiovascular disease
(CHD, peripheral arterial disease, myocardial infarction), n (%)
467 (18.9) 1,194 (31.7) 0.41 (0.36 to 0.47)
Stent insertion, n (%) 140 (5.6) 527 (13.9) 0.33 (0.27 to 0.40)
Heart valve dysfunction, n (%) 1106 (44.2) 1375 (36.1) 1.25 (1.12 to 1.39)
Variables Women (n=2546) Men (n=3866) Women-to-men OR* 95% CI
Heart valve replacement, n (%) 150 (6.0) 201 (5.3) 1.09 (0.88 to 1.37)
Heart failure, n (%) 653 (26.5) 1150 (30.6) 0.72 (0.64 to 0.80)
Previous ischaemic stroke/TIA/other ischaemic thromboembolic event, n (%) 406 (16.2) 555 (14.5) 1.04 (0.90 to 1.20)
Sinus rhythm at baseline, n (%) 823 (32.5) 1134 (29.5) 1.37 (1.22 to 1.53)
Adequate heart rate control (60–100 bpm) at baseline, n (%) 1077 (51.7) 1605 (51.0) 0.98 (0.87 to 1.09)
Medication
Antiplatelet agents, non-steroidal anti-inflammatory drugs,‡ n (%) 572 (22.6) 978 (25.5) 0.82 (0.73 to 0.93)
Antiarrhythmic drugs, n (%) 1594 (62.6) 2257 (58.4) 1.31 (1.18 to 1.46)
Mean and SD and number and percentages are presented. 
*Univariate ORs for gender were obtained by logistic regression adjusted for age and country. 
†CHA2DS2–VASc score included the extra point for female gender. 
‡Medication as used in the HAS-BLED score. Lack of guideline compliance indicates lack of treatment with oral anticoagulant in the previous 12 months despite guideline 
indication without contraindication.
AF, atrial fibrillation; CHA2DS2–VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke, vascular disease, age 65–74 years, sex 
category; CHD, coronary heart disease; EHRA, European Heart Rhythm Association; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history 
or predisposition, labile international normalised ratio, elderly, drugs/alcohol concomitantly; PREFER, PREvention oF thromboembolic events - European Registry;  
TIA, transient ischaemic attack. 
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Atrial fibrillation symptoms
Our findings that women with AF reported more symptoms 
than men are in line with recent reports that fairly consistently 
described a higher subjective symptom burden in women.14–16 
Truly asymptomatic AF, that is, no symptom history or current 
symptoms, was associated with the male gender in a prior obser-
vational registry study.17 Whether differences in illness percep-
tion and coping strategies or different major drivers causing 
Figure 1 Symptoms according to the European Heart Rhythm Association classification at baseline by gender. Percentages and 95% CI are provided. 
p Values are derived from Freeman-Halton’s extension of Fisher’s exact test.
Figure 2 Prevalence of anticoagulation therapy in patients with atrial fibrillation at baseline and after 1-year follow-up by gender. Percentages and 
95% CI are provided. p Values are derived from Freeman-Halton’s extension of Fisher’s exact test; baseline, p<0.0001; follow-up, p=0.001.
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AF underlie the lower symptom prevalence in men warrants 
further study.
Therapies to restore sinus rhythm
Despite more AF symptoms in women, men received more 
rhythm control interventions at baseline and also during the 
1-year follow-up; for example, both the prevalence and 1-year 
incidence of electrical cardioversion, pulmonary vein isolation 
or surgical therapy for AF were lower in women, whereas antiar-
rhythmic drug use was slightly higher. Recent publications show 
a similar pattern.16 The reason why women with AF were less 
likely to receive non-pharmacological interventions to maintain 
sinus rhythm remains unclear. Besides symptom burden, clinical 
factors such as the presence of heart disease and other comor-
bidities and patient preferences enter the decision process for 
catheter-based ablation therapy.18
In our cohort, women presented more often with valvular 
dysfunction but otherwise presented fewer risk factors, except for 
age, which may explain the observed more conservative treatment 
pattern. Data on other cardiovascular interventions suggest that 
women undergo a less aggressive treatment than men. In non-ST 
elevation myocardial infarction, women were treated invasively 
less frequently despite higher risk of adverse events19 or received 
cardiac devices (eg, cardiac resynchronisation therapy), less 
often than men.20 Current evidence suggests that AF treatments 
are as effective in women as in men,21 supported by the current 
guideline recommendations that state that catheter or surgical 
ablation techniques should be regarded as equally effective in 
women and men.7 The success rates of sinus rhythm restoration 
appear to be similar in both genders.22 A possible explanation for 
the treatment differences may be patient choice. Women tend 
to refuse multiple ablation procedures even after initial success, 
which results in a lower overall maintenance of sinus rhythm 
due to fewer repeat procedures compared with men.22 To which 
extent physician preferences and recommendations play a role in 
treatment differences remains to be examined.
Anticoagulation therapies
As recommended in the guidelines for AF treatment, antico-
agulation therapy was prescribed in the majority of patients, 
without any seeming difference between women or men. Similar 
results were reported in the Global Anticoagulant Registry in 
the Field–AF registry in 2014.17 Thus, positive changes can be 
demonstrated compared with earlier studies, which showed that 
women were less likely to receive oral anticoagulants compared 
with men.23 The uptake of NOACs during the follow-up was 
also similar in both genders, with a doubling from about 6% at 
baseline to 12% after 1-year follow-up. Considering evidence 
from a secondary analysis of NOAC trials24 25 and a recent 
meta-analysis,4 women appear to benefit from NOAC similarly 
to men. They may even have a higher net clinical benefit due to 
the high residual stroke risk in women treated with warfarin but 
lower stroke rates under NOAC therapy. Published data on the 
incidence of bleeding events are mostly from the warfarin era 
and have remained controversial regarding gender differences.26 
Whether the absence of gender differences in bleeding risk in 
our patient cohort may be explained by the broader application 
of NOACs during the 1-year follow-up or relate to a genuine 
lack of gender differences should be studied in the future.
Incidence of major outcomes
A higher risk of stroke and other arterial thromboembolic events in 
women has been reported, most recently in a large meta-analysis, 
which however showed substantial heterogeneity among studies.2 
Women in our study had 8% higher age-adjusted and coun-
try-adjusted odds of stroke/TIA/arterial thromboembolic events 
compared with men—an effect size much smaller than suggested 
by the meta-analysis. Due to the relatively short follow-up period 
Table 2 ORs for gender for baseline prevalence and 1-year incidence for treatments to restore sinus rhythm
Treatment
Baseline One-year follow-up
Women Men Women vs men Women Men Women vs men
N % N % OR 95% CI N % N % OR 95% CI
Pharmacological cardioversion 511 20.2 716 18.6 1.24 (1.08 to 1.41) 132 5.4 180 4.8 1.25 (0.99 to 1.59)
Electrical cardioversion 379 14.9 795 20.6 0.78 (0.68 to 0.90) 144 5.9 329 8.8 0.82 (0.67 to 1.01)
Ablation (pulmonary vein isolation) 84 3.3 243 6.3 0.72 (0.56 to 0.94) 68 2.8 170 4.5 0.88 (0.66 to 1.19)
Surgical therapy for atrial fibrillation 10 0.4 36 0.9 0.45 (0.22 to 0.93) 6 0.2 19 0.5 0.52 (0.20 to 1.31)
ORs are age and country adjusted.
Figure 3 Age-adjusted and country-adjusted women-to-men ORs for 1-year major outcomes. An OR below 1 indicates a lower risk of developing 
the outcome in women. TIA, transient ischaemic attack.
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of this study, the event numbers were small, and the uncertainty 
around our estimated effects were relatively large. At baseline, 
women accumulated a higher CHA2DS2–VASc score on average 
due to the extra point for female gender, which did not directly 
translate in a higher stroke risk during follow-up. Thus, the 
general addition of one point for gender, regardless of age, needs 
to be appraised carefully in practice. Women with a CHA2DS2–
VASc score of 1 are usually at a very low risk of stroke.27
Additionally, our results are derived from a cohort with a high 
proportion of adequate anticoagulation treatment. Underuse of 
anticoagulation in women despite relevant stroke risk has been 
suggested as another explanation for gender disparities in arte-
rial thromboembolic outcomes.15 26 The increased prescription 
of NOACs, with a possible more effective stroke risk reduction 
in women, may have contributed to smaller gender differences 
in stroke incidence.
AF has been recognised as a risk factor for myocardial infarc-
tion.6 28 Whether gender differences exist has remained contro-
versial. Whereas earlier reports did not show differences in 
myocardial infarction incidence,26 29 a recent population-based 
study observed a stronger association between AF and myocar-
dial infarction in women.30 Our current data, which included 
the whole spectrum of acute coronary syndromes, indicate that 
women were at a lower short-term risk than men. Similarly, the 
outcome of coronary revascularisation was more often seen in 
men than in women.
Heart failure is an important complication in individuals with 
AF. In the current analyses, we observed a higher incidence of 
heart failure in men over the 1-year follow-up period. We have 
previously described possible gender differences in the suscep-
tibility to heart failure in AF when examining subtypes of heart 
failure, that is, heart failure with preserved and reduced ejec-
tion fraction.5 Men had a higher incidence of heart failure with 
reduced ejection fraction, and women tended to have a higher 
risk of developing heart failure with preserved ejection fraction.
Clinical predictors of major outcomes revealed similar predic-
tive ability in both genders, with overall moderate discrimina-
tory ability. We observed possible differences in the strength of 
association in men compared with women. If validated, such 
differences may help estimate the risk factor burden and target 
AF treatment gender specifically. Despite being recently used 
to assess risk across diverse outcomes in patients with AF, the 
CHA2DS2–VASc and HAS-BLED scores performed similarly to 
our predictive models.
LIMITATIONS
As common in registries, the accuracy and completeness of data 
may be limited, despite a high degree of standardisation and 
training in data acquisition across enrolling centres, which may 
lead to bias. The results were obtained in individuals that sought 
medical attention due to the rhythm disorder and may thus not 
be generalisable to all patients with AF. Over the 1-year time 
span of the registry, the number of serious medical outcomes 
was also limited compared with the number of predictor vari-
ables examined. The PREFER in AF registry enrolled patients 
in seven Western European countries. Therefore, patient char-
acteristics, AF management and incidence of adverse events may 
not be generalisable to all European countries and other regions 
of the world. Such possible differences have been shown within 
the registry and are likely to be more pronounced for a compar-
ison with other countries.8 Whereas differences in treatment 
choice were observed across countries in our cohort, the relative 
proportions of women and men undergoing a specific treatment 
were comparable.
In summary, we demonstrated gender differences in the clin-
ical presentation, treatment and major clinical outcomes in a 
large, contemporary cohort, which call for gender-individual-
ised research and care. Guideline-recommended anticoagulation 
medication for AF was prescribed in both men and women, with 
a good uptake of NOACs in both genders. Women were less 
likely to receive non-pharmacological therapies to restore sinus 
rhythm despite being more symptomatic. The observed gender 
disparities require detailed pathophysiological and clinical 
workup and may provide the opportunity to develop gender-spe-
cific preventive and therapeutic strategies for a disease that is 
reaching epidemic proportions worldwide.
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